Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Restructuring Costs (2023)

Fate Therapeutics (FATE) has disclosed Restructuring Costs for 1 consecutive years, with $2.0 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Restructuring Costs changed N/A year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Dec 2023, changed N/A, and an annual FY2023 reading of $2.0 million, changed N/A over the prior year.
  • Restructuring Costs was $2.0 million for Q1 2023 at Fate Therapeutics.
  • Across five years, Restructuring Costs topped out at $2.0 million in Q1 2023 and bottomed at $2.0 million in Q1 2023.